Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb;18(2):247-249.
doi: 10.1038/s41423-020-00624-1. Epub 2021 Jan 8.

The interplay between dendritic cells and CD8 T lymphocytes is a crucial component of SARS-CoV-2 immunity

Jonas Buttenschön  1 , Jochen Mattner  2   3
Affiliations
Comment

The interplay between dendritic cells and CD8 T lymphocytes is a crucial component of SARS-CoV-2 immunity

Jonas Buttenschön et al. Cell Mol Immunol. 2021 Feb.

Erratum in

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
A numeric reduction and impaired interaction of DCs and T lymphocytes characterizes an acute infection with SARS-CoV-2. DCs release less type I interferon and express fewer chemokines and costimulatory molecules. Subsequently, the generation and expansion of SARS-CoV-2-specific CD4 and CD8 T cells is delayed, and the release of Th1 cytokines is impaired, resulting in enhanced viral replication
See this image and copyright information in PMC

Comment on

References

    1. Zhou R, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity. 2020;53:864–877.e865. doi: 10.1016/j.immuni.2020.07.026. - DOI - PMC - PubMed
    1. Law HK, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106:2366–2374. doi: 10.1182/blood-2004-10-4166. - DOI - PMC - PubMed
    1. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell. 2001;106:259–262. doi: 10.1016/S0092-8674(01)00456-1. - DOI - PubMed
    1. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529–536. doi: 10.1038/s41577-020-0402-6. - DOI - PMC - PubMed
    1. Hung IF, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395:1695–1704. doi: 10.1016/S0140-6736(20)31042-4. - DOI - PMC - PubMed